Advertisement
SAN MARCOS, Texas, Oct. 16 -- Today, Grifols S.A. (Grifols), a global healthcare company based in Barcelona, Spain, broke ground on a new national testing laboratory in San Marcos, Texas at a ceremony that included Federal, state and local officials. Construction of the laboratory represents the first phase of a multi-phase expansion that includes additional warehousing and production facilities. When completed, the new facilities will represent a $76 million capital investment and will complement Grifols' existing facilities in Los Angeles, California and Barcelona, Spain.
“San Marcos is proud to help bring the first global healthcare manufacturing facility of this type to the State of Texas," said San Marcos Mayor Susan Narvaiz. "This project represents a significant partnership with Grifols, the City of San Marcos, the State of Texas, and Hays County to create new jobs and a facility that will manufacture life-saving medicines."
“As the mother of a child who uses a plasma medicine and as an advocate for people with primary immunodeficiency diseases, Grifols expansion in San Marcos gives me great comfort that families like mine will have access to life-saving plasma medicines for years to come,” said Kathy Antilla, Director of Education for the Immune Deficiency Foundation, the national patient organization for people with primary immunodeficiency (PIDD) diseases. The plasma medicines Grifols produces are used to treat a variety of rare, chronic and often life-threatening diseases such as PIDD, hemophilia and other bleeding disorders, as well as shock, trauma and burns.
“We are pleased to make San Marcos home to our new facilities,” said Gregory Rich, President of Grifols, Inc., the company’s US division. “Business incentives offered by the City, County and State have helped us realize the goal of preparing for future patient needs of the critically important plasma medicines that we produce.” Texas is investing $500,000 in the Grifols expansion project through the Texas Enterprise Fund. The City and County provided substantial incentives to Grifols in the form of property tax relief.
Texas has been an important business hub for Grifols for many years. Currently the state is home to 17 Grifols donor centers and the company’s current testing laboratory in Austin. Grifols employs more than 600 Texans and contributes more than $80 million annually to the State’s economy through payroll and other business expenses. Plasma and intermediate products are often shipped to the Company’s Barcelona facilities through the port of Houston. Construction of the new laboratory, warehousing and production facilities in San Marcos will secure Texas as an essential long-term business home for the company.
About Grifols
Grifols S.A. is a Spain-based company in the healthcare sector involved in the research, development, manufacturing and marketing of plasma therapies, IV therapy solutions, enteral and parenteral nutrition, diagnostic systems, pharmacy automation, and medical materials and devices. Grifols plasma therapies are produced from plasma obtained at 80 donor centers across the US and are used to treat a variety of rare and life-threatening diseases. Founded in 1940, Grifols currently operates in 90 countries with more than 6,000 employees and 26 subsidiaries. Grifols is listed on the Ibex-35 stock market with combined gross revenues over euro 800 million.
For more information about Grifols please visit www.grifols.com.
SOURCE Grifols S.A.
Advertisement
“San Marcos is proud to help bring the first global healthcare manufacturing facility of this type to the State of Texas," said San Marcos Mayor Susan Narvaiz. "This project represents a significant partnership with Grifols, the City of San Marcos, the State of Texas, and Hays County to create new jobs and a facility that will manufacture life-saving medicines."
“As the mother of a child who uses a plasma medicine and as an advocate for people with primary immunodeficiency diseases, Grifols expansion in San Marcos gives me great comfort that families like mine will have access to life-saving plasma medicines for years to come,” said Kathy Antilla, Director of Education for the Immune Deficiency Foundation, the national patient organization for people with primary immunodeficiency (PIDD) diseases. The plasma medicines Grifols produces are used to treat a variety of rare, chronic and often life-threatening diseases such as PIDD, hemophilia and other bleeding disorders, as well as shock, trauma and burns.
“We are pleased to make San Marcos home to our new facilities,” said Gregory Rich, President of Grifols, Inc., the company’s US division. “Business incentives offered by the City, County and State have helped us realize the goal of preparing for future patient needs of the critically important plasma medicines that we produce.” Texas is investing $500,000 in the Grifols expansion project through the Texas Enterprise Fund. The City and County provided substantial incentives to Grifols in the form of property tax relief.
Texas has been an important business hub for Grifols for many years. Currently the state is home to 17 Grifols donor centers and the company’s current testing laboratory in Austin. Grifols employs more than 600 Texans and contributes more than $80 million annually to the State’s economy through payroll and other business expenses. Plasma and intermediate products are often shipped to the Company’s Barcelona facilities through the port of Houston. Construction of the new laboratory, warehousing and production facilities in San Marcos will secure Texas as an essential long-term business home for the company.
About Grifols
Grifols S.A. is a Spain-based company in the healthcare sector involved in the research, development, manufacturing and marketing of plasma therapies, IV therapy solutions, enteral and parenteral nutrition, diagnostic systems, pharmacy automation, and medical materials and devices. Grifols plasma therapies are produced from plasma obtained at 80 donor centers across the US and are used to treat a variety of rare and life-threatening diseases. Founded in 1940, Grifols currently operates in 90 countries with more than 6,000 employees and 26 subsidiaries. Grifols is listed on the Ibex-35 stock market with combined gross revenues over euro 800 million.
For more information about Grifols please visit www.grifols.com.
SOURCE Grifols S.A.
